TY - JOUR
T1 - Patenteral formulation of flavopiridol (NSC-649890)
AU - Dannenfelser, Rose Marie
AU - Surakitbanharn, Yosyong
AU - Tabibi, S. Esmail
AU - Yalkowsky, Samuel H.
PY - 1996/11
Y1 - 1996/11
N2 - Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'-chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cydodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen 's phosphate buffer pH 7.4.
AB - Flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6'-chloroflavone hydrochloride] is a flavonoid with weak electrolyte properties and an intrinsic aqueous solubility of 0.024 mg/mL. Neither cosolvency, complexation, nor pH control alone can produce an acceptable 10 mg/mL formulation that will not precipitate when diluted with blood. However, a combination of buffer and cyclodextrin or buffer and cosolvent can produce an acceptable 10 mg/mL formulation. In this paper, Flavopiridol is shown to be stable for at least one year in 30% hydroxypropyl β-cydodextrin/0.1 M citrate buffer (4.52). This formulation does not precipitate for at least one hour upon dilution with Sorensen 's phosphate buffer pH 7.4.
UR - http://www.scopus.com/inward/record.url?scp=0030483125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030483125&partnerID=8YFLogxK
M3 - Article
C2 - 9038080
AN - SCOPUS:0030483125
SN - 1079-7440
VL - 50
SP - 356
EP - 359
JO - PDA Journal of Pharmaceutical Science and Technology
JF - PDA Journal of Pharmaceutical Science and Technology
IS - 6
ER -